Dianox is a biotechnology company focused on developing innovative diagnostic self-tests for infectious diseases. Utilizing advanced biotechnology, Dianox's platform detects biomarkers in saliva, enabling rapid and non-invasive testing without the need for laboratory equipment. This approach significantly reduces exposure risk for medical staff and lowers testing costs by up to 80%. The company serves healthcare providers, research institutions, and potentially individual consumers, operating primarily in the global health diagnostics market. Dianox's business model revolves around the development and sale of diagnostic kits, with revenue generated through direct sales and partnerships with health organizations. The company is headquartered in Denmark, a leading biotech hub, and collaborates with development partners in Brazil and Germany. Recent milestones include a partnership with Rigshospitalet and recognition from Innobooster.

Keywords: diagnostic self-tests, infectious diseases, biotechnology, saliva-based testing, non-invasive, rapid detection, cost-effective, healthcare, global health, partnerships.